Edit
Elucid
https://www.elucidbio.com/Last activity: 19.07.2021
Active - Reference to Intraplaque Hemorrhage
Elucid is a medical technology company leveraging machine intelligence to improve the accuracy, experience, and cost-effectiveness of vascular diagnostic imaging. Its groundbreaking product, ElucidVivo, is the first FDA-cleared & CE-marked, histology-validated, non-invasive image analysis software for evaluating CTAs to provide multi-dimensional visualization, structural measurements, & plaque composition to inform risk of event (heart attack or stroke) and personalized treatment selection.
ElucidVivo is in use by cardiologists, vascular surgeons, radiologists, and neurologists across the US and EU at health systems, clinics, and research institutes. ElucidVivo has applications for coronary, carotid, and peripheral arteries.
In addition, Elucid also offers quantifying imaging services to evaluate the severity of vascular disease, in particular, atherosclerosis, and assess longitudinal therapeutic response to investigative therapeutic agents to vascular disease
ElucidVivo is in use by cardiologists, vascular surgeons, radiologists, and neurologists across the US and EU at health systems, clinics, and research institutes. ElucidVivo has applications for coronary, carotid, and peripheral arteries.
In addition, Elucid also offers quantifying imaging services to evaluate the severity of vascular disease, in particular, atherosclerosis, and assess longitudinal therapeutic response to investigative therapeutic agents to vascular disease
Location: United States, Massachusetts, Boston
Employees: 201-500
Total raised: $8M
Founded date: 2009
Investors 3
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.05.2021 | Series A | $8M | - |
Mentions in press and media 3
| Date | Title | Description |
| 19.07.2021 | Elucid Presents Data Demonstrating Its AI Software Can Uniquely Quantify Key Drivers of Heart Attack and Stroke From Computed Tomography | Elucid Founder, Andrew Buckler, To Present Findings at the SCCT Annual Scientific Meeting Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular dise... |
| 10.05.2021 | Daily funding roundup - May 10th, 2021 | Kin raised $63.9M; Vanta landed $50M; Blind picks up $37; Elucid secures $8M Forge Global: Forge Global is a San Francisco-based private securities marketplace. Forge Global has closed a new financing round with $150 million. Backers in the... |
| 10.05.2021 | Elucid Raises $8M in Series A Funding | Elucid, a Boston, MA-based medical technology company developing AI software to enable cardiovascular disease detection, raised $8M in Series A financing. The round was led by MedTex Ventures and Global Health Impact Fund. New and existing ... |